ClinicalTrials.gg
CompletedNCT06214130Updated Jan 23, 2024

Bioavailability of Orfiril Long 500 mg Prolonged-Release Minitablets and Ergenyl Chrono 500 mg Prolonged-Release Tablets

A Phase 1 interventional study of Sodium valproate 500 MG and Valproic Acid 500 MG in Multiple Drug Use, sponsored by Desitin Arzneimittel GmbH. Completed at 1 site in Canada. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-23.

Sponsored by Desitin Arzneimittel GmbH · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Sep 2023, registered Jan 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

Comparative bioavailability of valproate from Orfiril long 500 mg prolonged-release mini-tablets and Ergenyl chrono 500 mg prolonged-release tablets in healthy, male volunteers under fasting conditions.

Read the detailed description

Pivotal, multiple-dose, randomized, open-label, two-period, two-sequence, two-treatment, single-centre, crossover, study designed to evaluate the comparative bioavailability of valproate for Orfiril long 500 mg prolonged release minitablets and Ergenyl chrono 500 mg prolonged-release tablet once daily for 6 days in healthy male subjects under fasting conditions.

02

Conditions studied

  • Multiple Drug Use
03

In context

Lead sponsor

Desitin Arzneimittel GmbH is the lead sponsor of 13 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy, non-smoking (from at least 6 months prior to study drug administration), male volunteers, 18-65 years of age, inclusive.
  2. that was between 18.5 and 30.0 kg/m², inclusive.
  3. Healthy, according to the medical history, , vital signs, laboratory results and physical examination as determined by the PI/Sub-Investigator.
  4. Systolic blood pressure between 95-140 mmHg, inclusive, and diastolic blood pressure between 55-90 mmHg, inclusive, and heart rate between 50-100 bpm, inclusive, unless deemed otherwise by the PI/Sub-Investigator.
  5. Clinical laboratory values within BPSI's most recent acceptable laboratory test range, and/or values were deemed by the PI/Sub-Investigator as "Not ".
  6. Ability to comprehend and be informed of the nature of the study, as assessed by BPSI staff. Capable of giving written prior to any study- related procedure. Must have been to communicate effectively with clinic staff.
  7. Ability to fast for at least 14 hours and consume standard meals.
  8. Availability to volunteer for the entire study duration and was to adhere to all protocol requirements.
  9. Agreed not to have a tattoo or body piercing until the end of the study.
  10. Agreed not to receive the COVID-19 vaccination from 7 days prior to the first study drug dose until 7 days after the last study drug administration in the study.
  11. Agreed not to drive or operate heavy machinery if feeling dizzy or drowsy following study drug administration until full mental alertness was regained.
  12. Males who were able to father children must agree to use medically acceptable methods of and to not donate sperm during the study and for 60 days after the last study drug administration.

Medically acceptable methods of contraception include using a condom with a female partner of who was using oral contraceptives, hormonal patch, implant or injection, intrauterine device, or diaphragm with spermicide. Abstinence as a method of contraception is acceptable if it was in line with the preferred and usual lifestyle of the study participant.

If a subject's partner became pregnant during his participation in the study and for 60 days after he has completed his last study drug administration, he must have informed BPSI staff immediately.

Exclusion criteria

Exclusion Criteria:

Known history or presence of any hepatic, renal/genitourinary, gastrointestinal, cardiovascular, cerebrovascular, pulmonary, endocrine, immunological, musculoskeletal, neurological, psychiatric, dermatological or hematological disease or condition unless determined as not clinically significant by the PI/Sub-Investigator.

  1. Clinically significant history or presence of any clinically significant gastrointestinal pathology (e.g., chronic diarrhea, inflammatory bowel disease), unresolved gastrointestinal symptoms (e.g., diarrhea, vomiting), or other conditions known to interfere with the absorption, distribution, metabolism or excretion of the drug experienced within 7 days prior to first study drug administration, as determined by the PI/Sub-Investigator.
  1. Estimated \<70 ml/min. 4. Presence of any clinically significant illness within 30 days prior to first dosing, as determined by the PI/Sub-Investigator.
  1. Presence of any significant physical or organ abnormality as determined by the PI/Sub-Investigator.
  1. A positive test result for any of the following: , surface antigen, , drugs of abuse (marijuana, amphetamines, barbiturates, cocaine, opiates, phencyclidine and benzodiazepines), breath alcohol test and cotinine.
  1. Known history or presence of:
  • Alcohol abuse or dependence within one year prior to first study drug administration;
  • Drug abuse or dependence;
  • or idiosyncratic reaction to Orfiril Long, its , and/or related substances;
  • Suicidal ideation or suicidal behavior, as assessed by the Columbia Suicide Severity Rating Scale (baseline version) - Appendix B (Refer to Appendix 16.1.1)
  • Food allergies;
  • Presence of any dietary restrictions unless deemed by the PI/Sub-I as "Not Clinically Significant".
  • Family history of hereditary neurometabolic syndromes due to mitochondrial enzyme polymerase;
  • Family history of liver disease;
  • Known urea cycle disorder;
  • Known porphyria;
  • Coagulation disorder;
  • Severe allergic reactions (e.g., anaphylactic reactions, angioedema). 8. Intolerance to and/or difficulty with blood sampling through venipuncture. 9. Abnormal diet patterns (for any reason) during the four weeks preceding the study, including fasting, high protein diets etc.

    1. Individuals who have donated, in the days prior to first study drug administration:
  • 50-499 mL of blood in the previous 30 days;
  • 500 mL or more in the previous 56 days. 11. Donated plasma by plasmapheresis within 7 days prior to first study drug administration.

    1. Individuals who have participated in another clinical trial or who received an drug within 30 days prior to first study drug administration.
    1. Use of any enzyme-modifying drugs and/or other products, including strong inhibitors of cytochrome P450 (CYP) enzymes (e.g., cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP enzymes (e.g., barbiturates, carbamazepine, , phenytoin, St. John´s Wort, and rifampicin) in the previous 30 days before first study drug administration.
    1. Used of any monoamine oxidase (MAO) inhibitors (e.g., phenelzine, tranylcypromine) within 30 days prior to first study drug administration.
    1. Used of any prescription medication within 14 days prior to first study drug administration.
    1. Used of any over-the-counter medications (including oral multivitamins, herbal and/or dietary supplements) within 14 days prior to first study drug administration.
    1. Consumed food or beverages containing grapefruit and/or pomelo within 10 days prior to first study drug administration.
    1. Consumed food or beverages containing caffeine/methylxanthines, poppy seeds and/or alcohol within 48 hours before dosing in each study period.
    1. Individuals who had undergone any major surgery within 6 months prior to the start of the study, unless deemed otherwise by PI/Sub-Investigator.
    1. Difficulty with swallowing whole tablets. 21. Unable or unwilling to provide . 22. Had a tattoo or body piercing within 30 days prior to first study drug administration.
    1. A subject who, in the opinion of the investigator or designee, is considered unsuitable or unlikely to comply with the study protocol for any reason.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Test

    Orfiril long 500 mg (sodium valproate) prolonged-release minitablets

    Drug: Sodium valproate 500 MG · Drug: Valproic Acid 500 MG

  • Active comparator
    Reference

    Ergenyl chrono 500 mg (valproic acid) prolonged -release tablets

    Drug: Sodium valproate 500 MG · Drug: Valproic Acid 500 MG

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the curve during steady state (AUCtau, ss)

    Comparative bioavailability under fasting steady state conditions, the 90% confidence intervals (CI) for the Test/Reference ratios of geometric means for AUCtau,ss should fall within 80.00%-125.00%.

    Time frame: Day 6: pre-dose (0), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 18 and 24 hours post-dose.

  2. Maximal plasma concentration during steady state (Cmaxss)

    Comparative bioavailability under fasting steady state conditions, the 90% confidence intervals (CI) for the Test/Reference ratios of geometric means for AUCtau,ss should fall within 80.00%-125.00%.

    Time frame: Day 6: pre-dose (0), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 18 and 24 hours post-dose.

07

Study locations

1 site
  • Biopharma Services INC
    Toronto, M9L 3A2, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in Nov 2023, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2024
First posted
Jan 19, 2024
StartActual
Sep 22, 2023
Primary completionActual
Nov 6, 2023
CompletionActual
Nov 18, 2023
Last update
Jan 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06214130
Lead sponsor
Desitin Arzneimittel GmbH
Collaborators
BioPharma Services Inc.
Responsible party
Sponsor
First posted
Jan 19, 2024
Start date
Sep 22, 2023
Primary completion
Nov 6, 2023
Completion
Nov 18, 2023
Last update
Jan 23, 2024

Study contacts

Janice Faulknor, MD
principal investigator · BioPharma Services Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valproic Acid

Start the discussion